ResearcherInsermActive in the last 2 years
Angélique Vienot
Matched on ORCID iD 0000-0002-0381-7601; OpenAlex author ID A5071590361. Sources: OpenAlex.
Their work
- Papers
- 12 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 53
2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 3 papers
Papers 12
- CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy. Co-author DOI 10.1080/2162402x.2023.2294563↗
- Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Pha… Co-author DOI 10.1200/jco.23.00795↗
- Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery. Co-author DOI 10.3390/biomedicines12122754↗
- SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features. Co-author DOI 10.1002/1878-0261.13370↗
- Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Co-author DOI 10.1038/s41416-021-01341-w↗
- Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fonc.2021.683289↗
- FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. First author DOI 10.1634/theoncologist.2020-0577↗
- FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. Co-author DOI 10.4251/wjgo.v12.i3.332↗
- Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Co-author DOI 10.1016/j.clcc.2019.08.004↗
- A systematic review of economic evaluation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.08.035↗
- Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1093/jnci/djx037↗
- Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Co-author DOI 10.1038/bjc.2016.212↗
Closest collaborators
The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christophe Borg · 8 shared papers, 2017–2024 · strength 0.97
- Paper CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant c… DOI 10.1080/2162402x.2023.2294563↗
- Paper Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery. DOI 10.3390/biomedicines12122754↗
- Paper SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic… DOI 10.1002/1878-0261.13370↗
- François Ghiringhelli · 4 shared papers, 2023–2024 · strength 0.69
- Paper CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant c… DOI 10.1080/2162402x.2023.2294563↗
- Paper Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery. DOI 10.3390/biomedicines12122754↗
- Paper SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic… DOI 10.1002/1878-0261.13370↗
- Caroline Truntzer · 3 shared papers, 2023–2024 · strength 0.54
- Paper CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant c… DOI 10.1080/2162402x.2023.2294563↗
- Paper Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery. DOI 10.3390/biomedicines12122754↗
- Paper SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic… DOI 10.1002/1878-0261.13370↗
- Déwi Vernerey · 6 shared papers, 2016–2021 · strength 0.48
- Paper Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adeno… DOI 10.3389/fonc.2021.683289↗
- Paper FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. DOI 10.1634/theoncologist.2020-0577↗
- Paper FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based coho… DOI 10.4251/wjgo.v12.i3.332↗
- Cindy Neuzillet · 4 shared papers, 2017–2024 · strength 0.38
- Paper Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pan… DOI 10.1200/jco.23.00795↗
- Paper FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. DOI 10.1634/theoncologist.2020-0577↗
- Paper Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxali… DOI 10.1016/j.clcc.2019.08.004↗
- Christelle d’Engremont · 3 shared papers, 2017–2021 · strength 0.26
- Paper Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adeno… DOI 10.3389/fonc.2021.683289↗
- Paper FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based coho… DOI 10.4251/wjgo.v12.i3.332↗
- Paper Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. DOI 10.1093/jnci/djx037↗
- Christelle de la Fouchardière · 2 shared papers, 2021–2024 · strength 0.25
- Paper Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pan… DOI 10.1200/jco.23.00795↗
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Jean‐Baptiste Bachet · 2 shared papers, 2021–2024 · strength 0.25
- Paper Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pan… DOI 10.1200/jco.23.00795↗
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Nicolas Williet · 2 shared papers, 2021–2024 · strength 0.25
- Paper Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pan… DOI 10.1200/jco.23.00795↗
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Olivier Bouché · 2 shared papers, 2017–2024 · strength 0.21
- Coralie Schoumacher · 1 shared paper, 2024 · strength 0.20
- Anthony Turpin · 2 shared papers, 2020 · strength 0.19
- Hortense Chevalier · 2 shared papers, 2020 · strength 0.19
- Astrid Lièvre · 2 shared papers, 2019–2020 · strength 0.17
- Julien Edeline · 2 shared papers, 2019–2020 · strength 0.17
- Gerlinde Avérous · 1 shared paper, 2023 · strength 0.16
- Yves Rinaldi · 1 shared paper, 2024 · strength 0.15
- Gaël S. Roth · 1 shared paper, 2024 · strength 0.15
- David Malka · 1 shared paper, 2024 · strength 0.15
- Pascal R. Hammel · 2 shared papers, 2016–2020 · strength 0.15
- Franck Bonnetain · 2 shared papers, 2016–2017 · strength 0.10
- Christophe Louvet · 2 shared papers, 2016–2017 · strength 0.10
- Charlotte Peugniez · 1 shared paper, 2020 · strength 0.10
- Raëf Abdallah · 1 shared paper, 2021 · strength 0.10
- Léo Mas · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.